IQVIA to acquire the remaining 40% stake in Q2 Solutions from Quest Diagnostics for $760m.

IQVIA, a provider of advanced analytics, technology solutions, and clinical research services, agreed to acquire the remaining 40% stake in Q2 Solutions, a clinical trial laboratory services, from Quest Diagnostics, a provider of diagnostic information services, for $760m. "We are proud of our contributions to the growth of Q2 Solutions, and are confident that IQVIA has the strategic vision and agility to lead Q2 Solutions on the next phase of its journey as a global leader in central lab services," Steve Rusckowski, Quest Diagnostics Chairman, CEO and President.